Zoetis Inc. (NYSE: ZTS) today announced that the European Commission has granted the company a license for Stronghold® Plus (selamectin/sarolaner) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Zoetis Inc. (ZTS) PT Raised to $65 at Guggenheim Following 4Q ReportFebruary 16, 2017 11:59 AM Zoetis Receives European Commission Approval for Stronghold® PlusFebruary 15, 2017 4:30 PM